CoChat

STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma

Open access
Zhang, Peng, Rashidi, Aida, Zhao, Junfei, Silvers, Caylee, Wang, Hanxiang, Castro, Brandyn, Ellingwood, Abby, Han, Yu, Lopez-Rosas, Aurora, Zannikou, Markella, Dmello, Crismita, Levine, Rebecca, Xiao, Ting, Cordero, Alex, Sonabend, Adam M., Balyasnikova, Irina V., Lee-Chang, Catalina, Miska, Jason, Lesniak, Maciej S. · 2023 · Nature Communications
Cited by 234

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

As a key component of the standard of care for glioblastoma, radiotherapy induces several immune resistance mechanisms, such as upregulation of CD47 and PD-L1. Here, leveraging these radiotherapy-elicited processes, we generate a bridging-lipid nanoparticle (B-LNP) that engages tumor-associated myeloid cells (TAMCs) to glioblastoma cells via anti-CD47/PD-L1 dual ligation. We show that the engager B-LNPs block CD47 and PD-L1 and promote TAMC phagocytic activity. To enhance subsequent T cell recruitment and antitumor responses after tumor engulfment, the B-LNP was encapsulated with diABZI, a non-nucleotidyl agonist for stimulator of interferon genes. In vivo treatment with diABZI-loaded B-LNPs induced a transcriptomic and metabolic switch in TAMCs, turning these immunosuppressive cells into antitumor effectors, which induced T cell infiltration and activation in brain tumors. In preclinical murine models, B-LNP/diABZI administration synergized with radiotherapy to promote brain tumor regression and induce immunological memory against glioma. In summary, our study describes a nanotechnology-based approach that hijacks irradiation-triggered immune checkpoint molecules to boost potent and long-lasting antitumor immunity against glioblastoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-023-37328-9

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 234

Metadata

Authors
Zhang, P., Rashidi, A., Zhao, J., Silvers, C., Wang, H., Castro, B., Ellingwood, A., Han, Y., Lopez-Rosas, A., Zannikou, M., Dmello, C., Levine, R., Xiao, T., Cordero, A., Sonabend, A. M., Balyasnikova, I. V., Lee-Chang, C., Miska, J., & Lesniak, M. S.
Venue
Nature Communications
Published
2023-03-23
Volume
14
Issue
1
Pages
1610-1610
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4360611892
Cited by
234
References
20
FWCI
24.85
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma. https://app.cochat.ai/papers/10.1038/s41467-023-37328-9
The paper
Zhang, P., Rashidi, A., Zhao, J., Silvers, C., Wang, H., Castro, B., Ellingwood, A., Han, Y., Lopez-Rosas, A., Zannikou, M., Dmello, C., Levine, R., Xiao, T., Cordero, A., Sonabend, A. M., Balyasnikova, I. V., Lee-Chang, C., Miska, J., & Lesniak, M. S. (2023). STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma. Nature Communications. https://doi.org/10.1038/s41467-023-37328-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.